首页 > 最新文献

Lancet Rheumatology最新文献

英文 中文
Assessing the impact of health-care access on the severity of low back pain by country: a case study within the GBD framework 评估各国医疗服务的获取对腰背痛严重程度的影响:GBD 框架内的案例研究
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-07-16 DOI: 10.1016/S2665-9913(24)00151-6
YiFan Wu MPH , Sarah Wulf Hanson PhD , Garland Culbreth PhD , Caroline Purcell MD , Prof Peter Brooks MD , Prof Jacek Kopec PhD , Prof Lyn March PhD , Prof Anthony D Woolf FRCP , Maja Pasovic MEd MA , Erin Hamilton MPH , Damian Santomauro PhD , Prof Theo Vos PhD

Background

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is key for policy making. Low back pain is the leading cause of disability in terms of years lived with disability (YLDs). Due to sparse data, a current limitation of GDB is that a uniform severity distribution is presumed based on 12-Item Short Form Health Survey scores derived from US Medical Expenditure Panel Surveys (MEPS). We present a novel approach to estimate the effect of exposure to health interventions on the severity of low back pain by country and over time.

Methods

We extracted treatment effects for ten low back pain interventions from the Cochrane Database, combining these with coverage data from the MEPS to estimate the hypothetical severity in the absence of treatment in the USA. Severity across countries was then graded using the Health Access and Quality Index, allowing estimates of averted and avoidable burden under various treatment scenarios.

Findings

We included 210 trials from 36 Cochrane systematic reviews in the network analysis. The pooled effect sizes (measured as a standardised mean difference) for the most effective intervention classes were –0·460 (95% uncertainty interval –0·606 to –0·309) for a combination of psychological and physical interventions and –0·366 (–0·525 to –0·207) for surgery. Globally, access to treatment averted an estimated 17·6% (14·8 to 23·8) of the low back pain burden in 2020. If all countries had provided access to treatment at a level estimated for Iceland with the highest Health Access and Quality Index score, an extra 9·1% (6·4 to 11·2) of the burden of low back pain could be avoided. Even with full coverage of optimal treatment, a large proportion (65·9% [56·9 to 70·4]) of the low back pain burden is unavoidable.

Interpretation

This methodology fills an important shortcoming in the GBD by accounting for low back pain severity variations over time and between countries. Assumptions of unequal treatment access increased YLD estimates in resource-poor settings, with a modest decrease in countries with higher Health Access and Quality Index scores. Nonetheless, the large proportion of unavoidable burden indicates poor intervention efficacy. This method, applicable to other GBD conditions, provides policy makers with insights into health gains from improved treatment and underscores the importance of investing in research for new interventions.

Funding

Bill and Melinda Gates Foundation and Queensland Health.

背景全球疾病、伤害和风险因素负担研究(GBD)是制定政策的关键。就残疾生活年数(YLDs)而言,腰背痛是导致残疾的主要原因。由于数据稀少,GDB 目前的一个局限性是根据美国医疗支出小组调查 (MEPS) 得出的 12 项简表健康调查得分来推测严重程度的均匀分布。方法我们从 Cochrane 数据库中提取了 10 种腰背痛干预措施的治疗效果,并将其与 MEPS 的覆盖数据相结合,以估算美国在没有治疗的情况下的假定严重程度。然后使用 "健康获得和质量指数 "对各国的严重程度进行分级,从而估算出在不同治疗方案下避免和可避免的负担。最有效干预类别的集合效应大小(以标准化平均差衡量)为:心理和物理干预组合为-0-460(95%不确定区间为-0-606至-0-309),手术为-0-366(-0-525至-0-207)。在全球范围内,2020 年获得治疗估计可避免 17-6%(14-8 至 23-8)的腰背痛负担。如果所有国家都能按照健康可及性和质量指数得分最高的冰岛的估计水平提供治疗,则可避免额外9-1%(6-4至11-2)的腰背痛负担。即使最佳治疗实现了全覆盖,腰背痛负担中的很大一部分(65-9% [56-9 至 70-4])也是不可避免的。治疗机会不平等的假设增加了资源贫乏国家的YLD估计值,而在健康获得和质量指数得分较高的国家,YLD估计值略有下降。尽管如此,不可避免的负担所占比例较大,表明干预效果不佳。这种方法适用于其他 GBD 条件,为政策制定者提供了从改善治疗中获得健康收益的见解,并强调了投资研究新干预措施的重要性。
{"title":"Assessing the impact of health-care access on the severity of low back pain by country: a case study within the GBD framework","authors":"YiFan Wu MPH ,&nbsp;Sarah Wulf Hanson PhD ,&nbsp;Garland Culbreth PhD ,&nbsp;Caroline Purcell MD ,&nbsp;Prof Peter Brooks MD ,&nbsp;Prof Jacek Kopec PhD ,&nbsp;Prof Lyn March PhD ,&nbsp;Prof Anthony D Woolf FRCP ,&nbsp;Maja Pasovic MEd MA ,&nbsp;Erin Hamilton MPH ,&nbsp;Damian Santomauro PhD ,&nbsp;Prof Theo Vos PhD","doi":"10.1016/S2665-9913(24)00151-6","DOIUrl":"10.1016/S2665-9913(24)00151-6","url":null,"abstract":"<div><h3>Background</h3><p>The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is key for policy making. Low back pain is the leading cause of disability in terms of years lived with disability (YLDs). Due to sparse data, a current limitation of GDB is that a uniform severity distribution is presumed based on 12-Item Short Form Health Survey scores derived from US Medical Expenditure Panel Surveys (MEPS). We present a novel approach to estimate the effect of exposure to health interventions on the severity of low back pain by country and over time.</p></div><div><h3>Methods</h3><p>We extracted treatment effects for ten low back pain interventions from the Cochrane Database, combining these with coverage data from the MEPS to estimate the hypothetical severity in the absence of treatment in the USA. Severity across countries was then graded using the Health Access and Quality Index, allowing estimates of averted and avoidable burden under various treatment scenarios.</p></div><div><h3>Findings</h3><p>We included 210 trials from 36 Cochrane systematic reviews in the network analysis. The pooled effect sizes (measured as a standardised mean difference) for the most effective intervention classes were –0·460 (95% uncertainty interval –0·606 to –0·309) for a combination of psychological and physical interventions and –0·366 (–0·525 to –0·207) for surgery. Globally, access to treatment averted an estimated 17·6% (14·8 to 23·8) of the low back pain burden in 2020. If all countries had provided access to treatment at a level estimated for Iceland with the highest Health Access and Quality Index score, an extra 9·1% (6·4 to 11·2) of the burden of low back pain could be avoided. Even with full coverage of optimal treatment, a large proportion (65·9% [56·9 to 70·4]) of the low back pain burden is unavoidable.</p></div><div><h3>Interpretation</h3><p>This methodology fills an important shortcoming in the GBD by accounting for low back pain severity variations over time and between countries. Assumptions of unequal treatment access increased YLD estimates in resource-poor settings, with a modest decrease in countries with higher Health Access and Quality Index scores. Nonetheless, the large proportion of unavoidable burden indicates poor intervention efficacy. This method, applicable to other GBD conditions, provides policy makers with insights into health gains from improved treatment and underscores the importance of investing in research for new interventions.</p></div><div><h3>Funding</h3><p>Bill and Melinda Gates Foundation and Queensland Health.</p></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 9","pages":"Pages e598-e606"},"PeriodicalIF":15.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2665991324001516/pdfft?md5=8e167b58ec88f1ff73244d66e7292371&pid=1-s2.0-S2665991324001516-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141716826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards improving the Global Burden of Disease estimates for low back pain 努力改善腰背痛的全球疾病负担估计值
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-07-16 DOI: 10.1016/S2665-9913(24)00182-6
Mark Hancock , Alice Kongsted
{"title":"Towards improving the Global Burden of Disease estimates for low back pain","authors":"Mark Hancock ,&nbsp;Alice Kongsted","doi":"10.1016/S2665-9913(24)00182-6","DOIUrl":"10.1016/S2665-9913(24)00182-6","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 9","pages":"Pages e588-e589"},"PeriodicalIF":15.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141702226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient care 澳大利亚土著居民和托雷斯海峡岛民中的系统性红斑狼疮:消除差距和障碍,优化患者护理。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-07-03 DOI: 10.1016/S2665-9913(24)00095-X
The first inhabitants of Australia and the traditional owners of Australian lands are the Aboriginal and Torres Strait Islander peoples. Aboriginal and Torres Strait Islander peoples are two to four times more likely to have systemic lupus erythematosus (SLE) than the general Australian population. Phenotypically, SLE appears distinctive in Aboriginal and Torres Strait Islander peoples and its severity is substantially increased, with mortality rates up to six times higher than in the general Australian population with SLE. In particular, Aboriginal and Torres Strait Islander peoples with SLE have increased prevalence of lupus nephritis and increased rates of progression to end-stage kidney disease. The reasons for the increased prevalence and severity of SLE in this population are unclear, but socioeconomic, environmental, and biological factors are all likely to be implicated, although there are no published studies investigating these factors in Aboriginal and Torres Strait Islander peoples with SLE specifically, indicating an important knowledge gap. In this Review, we summarise the data on the incidence, prevalence, and clinical and biological findings relating to SLE in Aboriginal and Torres Strait Islander peoples and explore potential factors contributing to its increased prevalence and severity in this population. Importantly, we identify health disparities and deficiencies in health-care provision that limit optimal care and outcomes for many Aboriginal and Torres Strait Islander peoples with SLE and highlight potentially addressable goals to improve outcomes.
澳大利亚最早的居民和澳大利亚土地的传统拥有者是土著居民和托雷斯海峡岛民。原住民和托雷斯海峡岛民患系统性红斑狼疮(SLE)的几率是普通澳大利亚人的 2 到 4 倍。从表型上看,系统性红斑狼疮在土著居民和托雷斯海峡岛民中显得与众不同,其严重程度也大大增加,死亡率比一般澳大利亚系统性红斑狼疮患者高出六倍。特别是,患有系统性红斑狼疮的土著居民和托雷斯海峡岛民的狼疮性肾炎发病率更高,进展为终末期肾病的比率也更高。该人群系统性红斑狼疮患病率和严重程度增加的原因尚不清楚,但社会经济、环境和生物因素都可能与之有关,不过目前还没有针对系统性红斑狼疮原住民和托雷斯海峡岛民的这些因素的公开研究,这表明存在着重要的知识缺口。在本综述中,我们总结了有关土著居民和托雷斯海峡岛民系统性红斑狼疮的发病率、患病率、临床和生物学研究结果的数据,并探讨了导致该人群患病率和严重程度增加的潜在因素。重要的是,我们发现了在提供医疗保健服务方面存在的健康差距和不足,这些差距和不足限制了许多患有系统性红斑狼疮的土著居民和托雷斯海峡岛民获得最佳护理和治疗效果,并强调了改善治疗效果的潜在目标。
{"title":"Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient care","authors":"","doi":"10.1016/S2665-9913(24)00095-X","DOIUrl":"10.1016/S2665-9913(24)00095-X","url":null,"abstract":"<div><div>The first inhabitants of Australia and the traditional owners of Australian lands are the Aboriginal and Torres Strait Islander<span><span><span> peoples. Aboriginal and Torres Strait Islander peoples are two to four times more likely to have systemic lupus erythematosus (SLE) than the general Australian population. Phenotypically, SLE appears distinctive in Aboriginal and Torres Strait Islander peoples and its severity is substantially increased, with mortality rates up to six times higher than in the general Australian population with SLE. In particular, Aboriginal and Torres Strait Islander peoples with SLE have increased prevalence of </span>lupus nephritis and increased rates of progression to end-stage kidney disease. The reasons for the increased prevalence and severity of SLE in this population are unclear, but socioeconomic, environmental, and biological factors are all likely to be implicated, although there are no published studies investigating these factors in Aboriginal and Torres Strait Islander peoples with SLE specifically, indicating an important knowledge gap. In this Review, we summarise the data on the incidence, prevalence, and clinical and biological findings relating to SLE in Aboriginal and Torres Strait Islander peoples and explore potential factors contributing to its increased prevalence and severity in this population. Importantly, we identify </span>health disparities and deficiencies in health-care provision that limit optimal care and outcomes for many Aboriginal and Torres Strait Islander peoples with SLE and highlight potentially addressable goals to improve outcomes.</span></div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 10","pages":"Pages e713-e726"},"PeriodicalIF":15.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Painful scalp nodules in SAPHO syndrome. SAPHO 综合征的头皮疼痛性结节。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-07-03 DOI: 10.1016/S2665-9913(24)00161-9
Clément Triaille, Victor Kokta, Julie Powell, Jean Jacques De Bruycker
{"title":"Painful scalp nodules in SAPHO syndrome.","authors":"Clément Triaille, Victor Kokta, Julie Powell, Jean Jacques De Bruycker","doi":"10.1016/S2665-9913(24)00161-9","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00161-9","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experiences of telehealth during and after the COVID-19 pandemic and preferences for future care of people with systemic sclerosis: a cross-sectional study COVID-19 大流行期间和之后的远程医疗体验以及系统性硬化症患者对未来护理的偏好:一项横断面研究。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-26 DOI: 10.1016/S2665-9913(24)00166-8
{"title":"Experiences of telehealth during and after the COVID-19 pandemic and preferences for future care of people with systemic sclerosis: a cross-sectional study","authors":"","doi":"10.1016/S2665-9913(24)00166-8","DOIUrl":"10.1016/S2665-9913(24)00166-8","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 10","pages":"Pages e660-e663"},"PeriodicalIF":15.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pachydermodactyly: mimic of arthritis in a young man. 手足畸形:一名年轻男子关节炎的模拟病例。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-19 DOI: 10.1016/S2665-9913(24)00158-9
Cassandra Michelle Skinner-Taylor, Pablo Gamez-Siller, Brenda Cantu-Garza, Hector Guerra, Héctor Teodoro Rios-Bazaldua, Dionicio Angel Galarza-Delgado, Jesus Alberto Cardenas-de la Garza
{"title":"Pachydermodactyly: mimic of arthritis in a young man.","authors":"Cassandra Michelle Skinner-Taylor, Pablo Gamez-Siller, Brenda Cantu-Garza, Hector Guerra, Héctor Teodoro Rios-Bazaldua, Dionicio Angel Galarza-Delgado, Jesus Alberto Cardenas-de la Garza","doi":"10.1016/S2665-9913(24)00158-9","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00158-9","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engagement of people with lived experience in studies published in high-impact rheumatology journals: a meta-research review 让有生活经验的人参与在影响力大的风湿病学期刊上发表的研究:荟萃研究综述。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-18 DOI: 10.1016/S2665-9913(24)00165-6
{"title":"Engagement of people with lived experience in studies published in high-impact rheumatology journals: a meta-research review","authors":"","doi":"10.1016/S2665-9913(24)00165-6","DOIUrl":"10.1016/S2665-9913(24)00165-6","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 9","pages":"Pages e593-e595"},"PeriodicalIF":15.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research in Brief 研究简介
IF 25.4 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-17 DOI: 10.1016/S2665-9913(24)00163-2
Jennifer Thorley
{"title":"Research in Brief","authors":"Jennifer Thorley","doi":"10.1016/S2665-9913(24)00163-2","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00163-2","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 7","pages":"Page e421"},"PeriodicalIF":25.4,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141423968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contesting the BACPAP consortium's consensus – Authors' reply 质疑 BACPAP 联合会的共识 - 作者的回复
IF 25.4 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-17 DOI: 10.1016/S2665-9913(24)00130-9
Eva Kosek , Jo Nijs , Alessandro Chiarotto , Chad Cook , Lieven A Danneels , César Fernández-de-las-Peñas , Paul W Hodges , Bart Koes , Adriaan Louw , Raymond Ostelo , Gwendolyne G M Scholten-Peeters , Michele Sterling , Othman Alkassabi , Hana Alsobayel , Darren Beales , Paraskevi Bilika , Jacqui R Clark , Liesbet De Baets , Christophe Demoulin , Rutger M J de Zoete , Steven Z George
{"title":"Contesting the BACPAP consortium's consensus – Authors' reply","authors":"Eva Kosek ,&nbsp;Jo Nijs ,&nbsp;Alessandro Chiarotto ,&nbsp;Chad Cook ,&nbsp;Lieven A Danneels ,&nbsp;César Fernández-de-las-Peñas ,&nbsp;Paul W Hodges ,&nbsp;Bart Koes ,&nbsp;Adriaan Louw ,&nbsp;Raymond Ostelo ,&nbsp;Gwendolyne G M Scholten-Peeters ,&nbsp;Michele Sterling ,&nbsp;Othman Alkassabi ,&nbsp;Hana Alsobayel ,&nbsp;Darren Beales ,&nbsp;Paraskevi Bilika ,&nbsp;Jacqui R Clark ,&nbsp;Liesbet De Baets ,&nbsp;Christophe Demoulin ,&nbsp;Rutger M J de Zoete ,&nbsp;Steven Z George","doi":"10.1016/S2665-9913(24)00130-9","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00130-9","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 7","pages":"Pages e419-e420"},"PeriodicalIF":25.4,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141424327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital self-management for back pain in the UK 英国背痛的数字化自我管理
IF 25.4 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-17 DOI: 10.1016/S2665-9913(24)00164-4
The Lancet Rheumatology
{"title":"Digital self-management for back pain in the UK","authors":"The Lancet Rheumatology","doi":"10.1016/S2665-9913(24)00164-4","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00164-4","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 7","pages":"Page e411"},"PeriodicalIF":25.4,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141424328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1